Through ongoing collaborations with academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed is establishing a growing pipeline of drug candidates.

In November 2020, Seed entered into a research collaboration and license agreement with US pharma major Eli Lilly to discover and develop new chemical entities that could produce therapeutic benefit through targeted protein degradation.

Under the terms of the deal, New York-headquartered Seed will receive a $10 million upfront cash payment to fund research, as well as a $10 million equity investment from Lilly. Seed Therapeutics will also be eligible to receive up to approximately $780 million in potential pre-clinical and clinical development, regulatory and commercial milestones, as well as tiered royalties on net sales of products that result from the collaboration.